
Jean M Elwing

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/573945/publications.pdf Version: 2024-02-01



IFAN M FLWING

#	Article	IF	CITATIONS
1	Predictive value of incidental right ventricular abnormalities identified on SPECT for mortality and pulmonary hypertension. Journal of Nuclear Cardiology, 2022, 29, 1903-1914.	1.4	3
2	Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 198-207.	2.5	32
3	Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat. Pulmonary Circulation, 2022, 12, e12055.	0.8	6
4	Utilization of risk assessment tools in management of PAH: A PAH provider survey. Pulmonary Circulation, 2022, 12, e12057.	0.8	4
5	An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinil. Pulmonary Pharmacology and Therapeutics, 2021, 66, 101979.	1.1	1
6	Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. Annals of the American Thoracic Society, 2021, 18, 613-622.	1.5	27
7	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. Pulmonary Circulation, 2021, 11, 1-10.	0.8	17
8	Pulmonary Vascular Resistance Predicts Mortality and Graft Failure in Transplantation Patients With Portopulmonary Hypertension. Liver Transplantation, 2021, 27, 1811-1823.	1.3	16
9	Interhospital Transfer of Patients With Acute Pulmonary Embolism. Chest, 2021, 160, 1844-1852.	0.4	19
10	Healthâ€related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR). Pulmonary Circulation, 2021, 11, 1-11.	0.8	3
11	Successful use of intravenous treprostinil as a bridge to pulmonary thromboendarterectomy. BMJ Case Reports, 2021, 14, .	0.2	0
12	Predictors of outcomes following liver transplant in hepatopulmonary syndrome: An OPTN database analysis. Respiratory Medicine, 2021, 190, 106683.	1.3	5
13	Cardiac magnetic resonance imaging as a prognostic biomarker in treatment-naÃ ⁻ ve pulmonary hypertension. European Journal of Radiology, 2020, 123, 108784.	1.2	5
14	Improving adherence to pulmonary hypertension screening in patients with systemic sclerosis: Overcoming the provider-level barriers. Journal of Scleroderma and Related Disorders, 2020, 5, 219-223.	1.0	1
15	Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. Journal of Heart and Lung Transplantation, 2020, 39, 945-953.	0.3	15
16	Anticoagulation in pulmonary arterial hypertension: a decision analysis. Pulmonary Circulation, 2019, 9, 1-12.	0.8	5
17	Chronic Thromboembolic Pulmonary Hypertension. Clinics in Chest Medicine, 2018, 39, 605-620.	0.8	19
18	Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation. Pulmonary Circulation, 2017, 7, 167-174.	0.8	29

#	Article	IF	CITATIONS
19	A Unique Presentation of Anti-RNA Polymerase III Positive Systemic Sclerosis Sine Scleroderma. Case Reports in Rheumatology, 2016, 2016, 1-4.	0.2	2